Roche's Genentech unit has won FDA approval for Susvimo, an implant for eyesight-robbing disease wet age-related macular degeneration (AMD) that gives patients an alternative to regular injections ...

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

In addition to comparable BCVA levels, the researchers concluded that the PDS implant “provides effective, durable, and ...

Aviv Regev, executive vice president and head of Genentech Research & Early Development (gRED) NVIDIA’s push into the life sciences sector has been rewarded by a wide-ranging deal with Roche’s ...

SOUTH SAN FRANCISCO, Calif., March 05, 2025--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has accepted the ...

Swiss pharma giant Roche has announced the launch of the Roche Genentech Innovation Center Boston, USA, at Harvard’s Enterprise Research Campus in Allston which will further strengthen the ...

The new single-dose prefilled syringes will be available in 40 USP units/0.5mL and 80 USP units/mL dosage strengths. The Food and Drug Administration (FDA) has approved Purified Cortrophin ® Gel ...

Two companies have received approved for a generic of the 2.5 mg tablet of anticoagulant rivaroxaban, which is used to reduce the risk of stroke and deep vein thrombosis.

Ramiro Ribeiro, MD, PhD, shares insights from the ongoing research tyrosine kinase inhibitors for AMD and DME.